DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer

Tamim Niazi; Scott Williams; Ian D Davis; Martin R Stockler; Andrew James Martin; Wendy Hague; Karen Bracken; Margot Gorzeman; Felicia Roncolato; Sonia Yip; Lisa Horvath; Shomik Sengupta; Simon Hughes; Raymond S McDermott; James WF Catto; Neha Vapiwala; Wendy R Parulekar; Christopher Sweeney

Conference Proceedings

DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer

Tamim Niazi, Scott Williams, Ian D Davis, Martin R Stockler, Andrew James Martin, Wendy Hague, Karen Bracken, Margot Gorzeman, Felicia Roncolato, Sonia Yip, Lisa Horvath, Shomik Sengupta, Simon Hughes, Raymond S McDermott, James WF Catto, Neha Vapiwala, Wendy R Parulekar, Christopher Sweeney

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2020